Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-3467 Alone and in Combination with Olaparib in Participants with Advanced Solid Tumors (POLAR Trial)

The purpose of this study is to test how safe RP-3467 is when given alone and in combination with olaparib. Another purpose is to determine how safe different doses of RP- 3467 are when given alone and in combination with olaparib. RP-3467 is an investigational drug, which means that it has not been approved by the Food and Drug Administration (FDA). Olaparib is approved by the FDA but not approved in combination with RP-3467.

Are you Eligible? (Inclusion Criteria)

• Must be 18 years old or older - Ability to swallow oral medications - Life expectancy more than 12 weeks